Table 1.
Study | Design | Sample size | Mean age, y | Sex; no. of female participants and (%) |
Dementia assessment |
Follow-up |
---|---|---|---|---|---|---|
Giusti et al.45 | Prospective longitudinal cohort |
n=96 (home-based rehabilitation, n=41; institution-based rehabilitation, n=55); 96 patients with dementia | Home-based group: 84.1 (SD 5.4); institution-based group: 84.4 (SD 6.9) |
Home-based group: 36 (88); institution-based group: 49 (89) | SPMSQ | 3, 6, and 12 mo |
Goldstein et al.41 | Prospective longitudinal cohort |
n=58 (35 with impaired cognition [18 mild, 9 moderate, 8 severe]) |
84.0 (SD 6.7); 71–99 | 48 (83) | MDRS | ∼1 mo |
Heruti et al.47 | Prospective longitudinal cohort |
n=204 (173 with reported outcomes); 54 with impaired cognition; 199 normal cognition | 80 (SD 7.1); 65–97 | 156 (76) | MMSE | ∼1 mo |
Horgan and Cunningham13 |
Prospective | n=59 | No mean provided; median=80; IQR 73–87 |
54 (92) | AMTS | None |
Huusko et al.42 | Randomized controlled trial |
n=243 (132 with cognitive impairment [68 mild, 36 moderate, 28 severe]; 97 normal cognition) | Intervention group: 80 (67–92); control group: 80 (66–97) | Intervention group: 84 (70), control group: 90 (73) | MMSE | 3 mo and 1 y |
Lenze et al.19 | Prospective cohort |
n=97 (20 [51%] SNF impaired cognition; 18 [31%] IRF impaired cognition) | 81.7 (SD 8.8) | 79 (81) | MMSE | 2 and 12 wk |
McGilton et al.20 | Longitudinal retrospective |
n=31 (17 impaired cognition; 14 normal cognition) | 87 | 18 (58) | MMSE | None |
Naglie et al.43 | Randomized controlled trial |
n=280 (74 impaired cognition; 205 normal cognition) | Interdisciplinary care group: 83.8 (SD 6.9); usual care group: 84.6 (SD 7.3) | Interdisciplinary care group: 109 (77); usual care group: 114 (83) | SPMSQ | 3 and 6 mo |
Penrod et al.48 | Prospective cohort |
n=443 (93 impaired cognition; 350 normal cognition) | 81.4 (SD 8.7); 53–101 | 363 (82) | Self-reported as present or not present | 2 and 6 mo |
Rolland et al.22 | Prospective cohort |
n=61 (8 impaired cognition [MMSE <20]; 23 possible impaired cognition [MMSE 20–27]; 10 without cognitive impairment [MMSE >27]) | MMSE <20: 87.6 (SD 7.2); MMSE 20–27: 83.9 (SD 6.8); MMSE >27: 77.6 (SD 7.4) |
MMSE <20: 25 (41); MMSE 20–27: 17 (28); MMSE >27: 8 (13) | MMSE | ∼2 mo |
Stenvall et al.46 | Randomized controlled trial |
n=199 (64 impaired cognition; 135 normal cognition) | Intervention group: 82.3 (SD 6.6); control group: 82.0 (SD 5.9) | Intervention group: 74 (73); control group: 74 (76) | MMSE | Hospitalization period |
Uy et al.40* | Randomized controlled trial |
n=11* (11 impaired cognition) | Intervention group 83; control group 80 | 11 (100) | SPMSQ | 1 and 4 mo |
Vidan et al.44 | Randomized controlled trial |
n=319 (78 impaired cognition; 241 normal cognition; intervention group 39 [25%]; usual-care group 39 [24%]) | Intervention group: 81.7 (SD 7.8); usual care group: 82.6 (SD 7.4) | Intervention group: 131 (85); usual care group: 129 (79) | Goldman Scale | 3, 6, and 12 mo |
Restricted to nursing-home residents with cognitive impairment.
SPMSQ=Short Portable Mental Status Questionnaire; MDRS=Mattis Dementia Rating Scale; MMSE=Mini Mental State Exam; AMTS=Abbreviated Mental Test Score; IRF=in-patient rehabilitation facility; SNF=skilled nursing facility.